More selective pharmacologic interventions, including AR antagonists like enzalutamide, apalutamide, and darolutamide, directly block AR transcriptional activity [64] and have shown efficacy in metastatic prostate cancer, though their use in melanoma remains investigational [15,66,67]. This evidence concerns the gene AR and metastatic prostate carcinoma.